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Abstract 
Importance: The effectiveness of lipid-lowering, blood pressure-lowering, and aspirin treatment for 
prevention of cardiovascular disease (CVD) differs between individuals with type 2 diabetes (T2DM).  
Objectives: To develop and externally validate a Diabetes Lifetime-perspective prediction (DIAL) 
model, for individualising CVD prevention in people with T2DM by predicting  reduction of 10-year 
CVD-risk and years gained without incident or recurrent myocardial infarction or stroke. 
Design: The model was developed using a random 75% of people with T2DM registered in the Swedish 
National Diabetes Registry (NDR; n=292,024) between 2002 and 2012. Internal validation was 
performed using the remaining 25% of the Swedish NDR (n=97,342). External validation was performed 
using data on people with T2DM included in the ADVANCE, ACCORD, ASCOT and ALLHAT-LLT-
trials, the SMART and EPIC-NL-cohorts, and the Scottish diabetes register, pooled by geographical 
region. 
Setting: Primary care and hospital-based practice. 
Participants: People with T2DM: 389,366 from Sweden, 167,731 from Scotland, 7,742 from other parts 
of Western-Europe, 2,142 from Eastern-Europe, 14,590 from North-America and 5,580 from Asia and 
Oceania. 
Predictors: Age, sex, current smoking, duration of T2DM, insulin treatment, systolic blood pressure, 
body mass index, haemoglobin A1c, non-high-density lipoprotein cholesterol, estimated glomerular 
filtration rate, albuminuria, and history of CVD. Hazard ratios for treatment effects were derived from 
published meta-analyses. 
Main Outcome(s) and Measure(s): CVD-events (vascular mortality, stroke or myocardial infarction), 
non-vascular mortality, and CVD-free survival derived from two complementary competing risk adjusted 
Cox proportional hazards functions. Predicted treatment effect in years gained without myocardial 
infarction, stroke, or death is defined as the difference in median survival with and without treatment. 
Results: Predicted and observed CVD-free survival showed good agreement in all validation sets. The c-
statistic for the prediction of CVD was 0.83 for internal and 0.64 to 0.65 for external validation. 
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Treatment effects in CVD-free life years gained can be predicted for individuals with T2DM using an 
interactive calculator.  
Conclusions and Relevance: CVD-free life expectancy and effects of lifelong CVD prevention in terms 
of CVD-free life years gained can be accurately estimated for people with T2DM using readily available 
clinical characteristics. The prediction of individual-level treatment effect may facilitate personalised 
treatment and support informed decision-making and patients’ motivation to comply with prescribed 
treatments. 
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Introduction 
People with T2DM are at up to 2-fold increased risk for cardiovascular disease (CVD) compared to 
people without T2DM independently from other risk factors.1 Estimated reductions in life expectancy and 
quality adjusted life years (QALYs) due to CVD are substantial in people with T2DM especially in 
people diagnosed with T2DM at young ages.2 3 International guidelines on CVD prevention recommend 
lipid-lowering and blood pressure-lowering treatment to achieve cholesterol- and blood pressure targets. 
As treatment effects may vary greatly between people due to differences in baseline risk, a more 
individualised approach based on absolute individual CVD-risk should be considered.4-8 In general, 
people with higher individual cardiovascular risk will benefit more in absolute terms from lipid-lowering 
or blood pressure lowering than people with a lower cardiovascular risk. As these treatments are usually 
used lifelong, it is important to take into account long-term CVD-risk in addition to shorter term risk such 
as five or 10 year risk as used in many risk scores.9 
The use of CVD risk prediction models for people with T2DM, such as the UKPDS, ADVANCE, 
Fremantle, and New Zealand Diabetes risk scores has been recommended in various national 
guidelines.10-22 Long-term CVD-risk and CVD-free life expectancy can also be estimated. The latter is the 
expected number of remaining life years without the occurrence of an incident or recurrent myocardial 
infarction or stroke, which may be more informative to patients and healthcare providers than an estimate 
of risk.23-25 Most existing prediction models predict 5-year risks of CVD12, however, in people under 50 
years of age life expectancy is usually much longer than 5 years. The treatment goal may then be to 
prevent CVD later in life. As 5-year CVD-risk in younger people is nearly always low, the potential long-
term benefit of preventive drug-treatment is frequently underestimated. This may lead to delays in 
prescribing effective interventions in younger people. As age is such an important risk factor for CVD the 
majority of older people are eligible for treatment. However, as older people are also at risk for other 
diseases and mortality from both vascular and non-vascular causes (i.e. competing risks), reductions in 
CVD-risk may not always result in life years gained. This decreased potential to benefit from preventive 
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treatment due to competing risks is not taken into account in existing risk models and may contribute to 
the over-estimation of the effect of preventive treatment in older people.26 27 
The objective of the present study was to develop and externally validate a Diabetes Lifetime-perspective 
prediction (DIAL) model,  for individualising lifelong CVD prevention with lipid-lowering, anti-
hypertensive, and aspirin treatment in people with T2DM by predicting 10-year CVD-risk, CVD-free life 
expectancy, and treatment effects in terms of CVD-free life years gained:. Notably, CVD-free life 
expectancy for a person with a history of CVD should be interpreted as time without recurrent myocardial 
infarction or stroke. 
 
Methods 
Sources of data 
The Swedish National Diabetes Registry (NDR) and the Scottish Care Information (SCI) –Diabetes 
database are population wide registers. The secondary Manifestation of ARTerial disease (SMART) study 
and European Prospective Investigation into Cancer-Netherlands (EPIC-NL) are prospective cohort 
studies and Action to Control Cardiovascular Risk in Diabetes (ACCORD), the Action in Diabetes and 
Vascular disease: preterAx and diamicroN-MR Controlled Evaluation (ADVANCE), Anglo-Scandinavian 
Cardiac Outcomes Trial (ASCOT) and the Lipid Lowering Trial component of the Antihypertensive and 
Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT) are randomised controlled 
trials, all including people with T2DM. Study details have been described elsewhere.28-37 The prediction 
model was developed in the Swedish NDR and externally validated in the remaining datasets. Definitions 
of T2DM used in each study are provided in supplemental table 1. All use of registers data, cohort and 
trial studies were approved by institutional review boards and all participants gave written informed 
consent before taking part in the cohorts and trials. 
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Participants 
Participants were people aged >18 years with a diagnosis of T2DM with or without prevalent CVD. 
People with a previous diagnosis of cancer (ICD-10 codes C00-C97) or stage 4 or 5 chronic kidney 
disease (estimated glomerular filtration rate, eGFR <30 mL/min) were excluded. A comprehensive 
overview of the eligibility criteria for the original cohorts and trials are provided in supplemental table 1.  
 
Outcomes 
CVD was defined as a non-fatal myocardial infarction, non-fatal stroke, or vascular mortality. In the 
Swedish NDR and the SCI –Diabetes database, this is based on linkage to cause of death registers and 
hospital discharge registers using ICD-10 codes (non-fatal myocardial infarction: ICD-10 code I21; non-
fatal stroke ICD-10 code I61, I63, I64; vascular mortality: ICD-10 codes I20-I25, I46.0, I46.1, I46.9, I61, 
I63, and I64). For all cohort and trial data, the endpoint definitions are described in supplemental table 1. 
There was blinding to randomisation group for assessment of outcomes in trial participants. Non-vascular 
mortality was defined as all deaths other than those with a cardiovascular cause identified in the above 
list. 
 
Predictors 
Predictors were predetermined based on existing diabetes risk scores and availability in routine clinical 
practice.13-19 21 Baseline data for people registered in the Swedish NDR and SCI –Diabetes database were 
data collected in the first year after registration. In the other data sources, the baseline data were measured 
at study entrance prior to follow-up. Eleven predictors were selected; sex (female/male), current smoking 
(yes/no), systolic blood pressure (SBP in mmHg), body-mass index (BMI in kg/m²), haemoglobin A1c 
(HbA1c in mmol/l), eGFR  (ml/min), non-high-density lipoprotein cholesterol (non-HDLc in mmol/l), 
albuminuria (no/micro/macro), duration of T2DM (years since diagnosis), insulin treatment (yes/no), 
history of CVD (yes/no). Micro-albuminuria was defined as an albumin/creatinine ratio 3-30 mg/mmol or 
urine-albumin 20-300mg/l, and macro-albuminuria was defined as an albumin/creatinine ratio 
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>30mg/mmol or urine-albumin >300mg/l. Prescriptions for preventive medication for CVD were not 
selected as a predictor, because this would interfere with the predictions of treatment effects of these 
medication. Socio economic status was not selected due to limited availability in many datasets. 
 
Missing data 
To account for missing data in the predictors, single imputation by predictive mean matching was used 
for each of the original cohorts separately (aregImpute in R, Hmisc package).38 In the validation cohorts, 
some predictors were not recorded at all. For cohorts where HbA1c was not measured for any participant 
(i.e. ALLHAT and ASCOT), values were estimated using available plasma glucose levels assuming 
measured glucose levels to be average glucose levels (Glucose (mmol/l) = 1.59*HbA1c (%) – 2.59, thus 
HbA1c (%) = (Glucose (mmol/l)+2.59)/1.59).39 For all other missing predictors in the validation dataset, 
data were imputed to the median value of the Swedish NDR. The number, proportions and type of 
missing data in each dataset are described in the supplemental methods. 
 
Statistical analysis 
Handling continuous predictors 
Continuous predictors were truncated at the 1st and 99th percentile to limit the effect of outliers. Log-
linearity of the relationship between continuous predictors and the outcomes was tested with restricted 
cubic splines and transformations were applied when this improved model fit based on Akaike’s 
Information Criterion.  
 
Development of the lifetime model 
A random sample of 75% of people from the Swedish NDR (n=292,024) was used as the development 
dataset. Using these data, we developed two complementary Fine and Gray competing risk adjusted Cox 
proportional hazard models with left truncation and right censoring: one for the prediction of CVD events 
using non-vascular mortality as the competing endpoint (i.e. model part A), and another for the prediction 
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of non-vascular mortality using CVD events as the competing endpoint (i.e. model part B). These 
statistical methods have been described in detail previously.23 40 Briefly, age was used as the time-scale 
and therefore people in the development dataset contributed data to the survival model from their age at 
study entry until the time of an event or censoring, defined by the age at study exit. As a result, estimates 
derived from these models are not limited by follow-up time but by the age distribution of study 
participants. However, predictions are unstable where the number of people and number of events in a 
specific age group is limited. . The age-range was therefore limited to between 30 and 95 years (number 
of people <30 years: 2,045, number of people >95 years: 2,501) for estimation of CVD-free life 
expectancy. The two competing risk adjusted Cox proportional hazard functions were then recalibrated 
based on the incidence of CVD and incidence of non-vascular mortality using the expected versus 
observed ratio. The age-specific baseline survival for both Cox proportional hazard functions were 
centred for continuous variables (BMI of 30 kg/m2, systolic blood pressure of 140 mmHg, non-HDLc of 
3.8 mmol/l, HbA1c of 50 mmol/l, and eGFR of 80 ml/min) for practical reasons and to avoid rounding 
errors. The proportional hazards assumption was assessed by inspection of the correlation plots between 
scaled Schoenfeld residuals for the various predictors and age. Transformations and non-proportionality 
of predictors were described in the supplemental methods. Where interaction existed between a predictor 
and age, the HR for that predictor is shown for the median age of 65 years. The HR for transformed 
predictors is shown for the 75th percentile versus the 25th percentile. The sample size was more than 
sufficient by conventional assessment for prediction models with >1000 endpoints per variable.41  
 
Predictions for individual persons 
Calculations of CVD-free life expectancy (i.e. median survival without incident or recurrent myocardial 
infarction, stroke, or vascular death) were based on life-tables with one-year time intervals. An example 
of such a life-table for an individual person is shown in supplemental table 2. Starting at the current age of 
an individual with T2DM, the risk of having a CVD-event (at) and the risk of dying from non-vascular 
causes (bt) were predicted for each future life-year. Next, the cumulative CVD-free survival (Survt+1) was 
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calculated by multiplying the survival probability at the beginning of each life-year (Survt) by the CVD-
free survival probability during that year (Survt - at - bt). Obviously the cumulative CVD-free survival 
started at 100% at the current age of a person. This process was repeated until the maximum age of 95 
years. CVD-free life expectancy of an individual was defined as the median survival without myocardial 
infarction or stroke or death, which was the age where the estimated cumulative survival drops below 
50%. Similarly, 10-year CVD-risk was calculated by summation of the predicted cause-specific CVD risk 
in the first 10 years from a person’s current age onwards. The cause-specific CVD-risk was obtained by 
multiplication of the chance of survival without a CVD-event at the beginning of each year (Survt) and 
the risk of having a CVD-event (at) during that year. 
 
Model validation 
Internal validation of the lifetime model was performed in the remaining random sample of 25% of 
people in the Swedish NDR (n=97,342) for 10 year risk predictions. External validation was performed 
using pooled cohorts based on geographical origin of people originating from the SCI –Diabetes database, 
SMART, EPIC-NL, ACCORD, ADVANCE, ASCOT, and ALLHAT cohorts. The selected regions were 
continents, with a subdivision for Europe. Five-year risks were predicted for Western-Europe, Eastern-
Europe, North-America, Asia and Oceania, and 10 year risks for Scotland. Although Scotland is part of 
Western-Europe, this was a separate validation dataset, due to both the longer follow-up and the 
population-based nature of the dataset. In addition, the comparatively large number of people in 
Scotland’s diabetes register overwhelmed the number of people in other countries in Western-Europe. 
Supplemental table 3 presents the number of people allocated from each original cohort to each pooled 
geographical cohort and the number of events occurred in each pooled cohort.  
Goodness of fit was assessed for CVD-free survival, vascular event, and non-vascular mortality models 
separately using calibration plots.42 The models were recalibrated based on the incidence of CVD and 
incidence of non-vascular mortality using the expected versus observed ratio in all separate datasets. The 
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logarithm of the expected versus observed ratio was subtracted from the linear predictor. Discrimination 
was quantified using c-statistics.  
 
Prediction of individual treatment effect 
We combined competing risk adjusted Cox proportional hazard function A for prediction of CVD with 
hazard ratios from randomised trials or meta-analyses to predict the individual treatment effect and 
lifetime benefit of treatment. This method of calculating projected individual treatment effects has 
previously been applied by the American Heart Association and American College of Cardiology in their 
‘ASCVD risk estimator plus’ based on the Pooled Cohort Equations for primary prevention.43 By using 
life-tables, any gains in CVD-free survival will automatically be adjusted for competing risks by 
increasing the time at risk for non-CVD mortality. In this study, we derived estimates of the effect of 
lipid-lowering, blood pressure-lowering, and aspirin treatment.44-49 The hazard ratios for different 
medications used to estimate treatment effects are described in the supplemental methods. The lifetime 
benefit of treatment for an individual person was calculated as the difference between the predicted 
median CVD-free life expectancy with and without treatment. Similarly, 10-year absolute CVD-risk 
reduction for individual persons were estimated by calculating the difference between the predicted 10-
year CVD-risk with and without treatment. 
 
Results 
The selection of development and validation cohorts from the Swedish NDR is illustrated in figure 1. Of 
the 292,024 people in the derivation cohort, 21,910 (8%) experienced a CVD event and 45,479 (16%) 
died of non-vascular causes during follow-up. Of the 97,342 people forming the interval validation 
dataset, 7,352 (8%) experienced a CVD event and 15,093 (16%) died of non-cardiovascular causes during 
follow-up. Baseline characteristics of all other study populations are described pooled by geographical 
origin in table 1, and stratified by original study cohort in supplemental table 4. 
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Development of the DIAL model 
The calculation formulae including the coefficients of the Cox proportional hazard functions, age-specific 
baseline survivals, and HRs of intended treatment of the model are provided in supplemental table 5 and 
6. The hazard ratios (HRs) for Cox proportional hazard functions A and B of the DIAL model are shown 
in table 2. Cox proportional hazard function B was recalibrated in the internal validation based on the 
expected versus observed ratio of 0.81 for incidence of non-vascular mortality. 
 
Internal validation 
After  recalibration for differences in predicted and observed non-vascular death rates predicted 10-year 
risk for CVD and all-cause mortality (CVD risk and non-vascular mortality risk combined) showed good 
agreement with the 10-year observed risk in the development dataset (figure 2). Discrimination of the 
estimated 10-year CVD risk was 0.83 (95% CI 0.83 to 0.84), discrimination of 10-year non-vascular 
mortality risk was 0.72 (0.72-0.73) and 10-year risk for CVD and all-cause mortality was 0.77 (0.76-
0.77).  
 
External validation 
The predicted 5-year risk for CVD and all-cause mortality showed good agreement with the observed 5-
year CVD-free survival in Western-Europe, Eastern-Europe, North-America and Asia and Oceania 
(figure 3). Discrimination of the estimated 5-year CVD-risk was between 0.64 and 0.65. C-statistics for 5-
year non-vascular mortality risk (range 0.59-0.67) and 5-year risk for CVD and all-cause mortality (range 
0.64-0.69) are shown in supplemental table 7. CVD event rates were higher in the Scottish Care 
Information –Diabetes database (17 per 1000 people per year) compared to the Swedish NDR (11 per 
1000 people per year). Recalibration was necessary to take differences in CVD-risk between high and low 
risk countries, into account. The Cox proportional hazard functions A and B were updated for differences 
in average predicted and observed event rates in the Scottish diabetes registry with an expected versus 
observed ratio of 0.17 and 1.34 respectively. After updating the model for differences in predicted and 
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observed event rates, external validation in Scottish data showed good agreement between the predicted 
and observed 10-year risk for CVD and all-cause mortality (figure 3). Discrimination of 10-year CVD-
risk was 0.64 (95% CI 0.64 to 0.65; supplemental table 7). 
 
Individual lifetime estimates and treatment effects for people with T2DM 
Patient characteristics can be entered in the decision support tool together with the intended and current 
treatment to estimate individual CVD-free survival and CVD-free life years gained of preventive 
treatment (Appendix: Excel calculator). An example of the differences in expected treatment effect 
between individuals derived from the decision support tool is that a combination therapy of simvastatin 
40mg, ezetimibe 10mg and systolic blood pressure-lowering to 140mmHg, conferred between 0.04 and 
12.5 years gained without CVD in people enrolled in the Swedish NDR.  People who were 78 years or 
older, without a history of vascular disease, systolic blood pressure of <140mmHg, and LDL-c of <3.0 
mmol/L at baseline gained <0.05 CVD-free years. People aged between 55 and 70 years old, with a 
history of vascular disease, systolic blood pressure >160 mmHg and LDL-c >3.0 mmol/L at baseline had 
a lifetime benefit of>10 years. Figure 4 illustrates the results of applying the decision support tool to three 
additional individual examples of people with T2DM with differing baseline characteristics. 
 
Discussion 
In this study we have developed and validated the DIAL model to predict CVD-free life expectancy and 
10-year CVD risk in people with T2DM using widely available patient characteristics. This is the first 
model for people with T2DM that predicts 10-year CVD risk, CVD-free life expectancy, and lifetime 
benefit in CVD-free life years gained. This enables the identification of likely long-term benefit of 
preventive treatment for people with T2DM. By taking into account the competing risk of non-CVD 
mortality, the model can reliably estimate treatment effects. Therefore, the DIAL-model offers additional 
functionality compared to existing risk scores for people with T2DM (i.e. mainly 5-year absolute risk for 
people with T2DM) that tend to underestimate risk and benefits of treatment in younger people and 
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overestimate risk and benefits in older people.13-19 21 Increasing incidence of T2DM in younger people and 
the marked increases in prevalence of type 2 diabetes in elderly people means that assessing CVD risk 
accurately and treating it appropriately is essential for individuals, health systems and societies. 
We have validated the DIAL model in populations from different continents and have demonstrated that, 
after re-calibration, it has the potential to support medical decision-making for CVD prevention in people 
with T2DM in diverse populations. The discriminative ability of the model was moderate in each external 
validation dataset consistent with external validation of previous risk scores. For example validation of 
the ADVANCE risk score in EPIC-NL and SMART gave C-statistics of 0.62 and 0.68 respectively.22 The 
cardiovascular event rate was higher in Scotland compared to Sweden, due to differences in multiple 
factors not taken into consideration in the model, including lifestyle differences. Recalibration of the 
DIAL model using the expected/observed ratios of incidence of CVD and mortality allows it to be 
adapted for use in populations with varying levels of CVD risk. Users can choose to apply either the CVD 
event rate for Sweden (11/1000 people per year) or for Scotland (17/1000 people per year) whichever is 
more appropriate for their population.  
Several studies have convincingly demonstrated the advantage of lifetime prediction compared to 
traditional 5-year or 10-year risk predictions. A microsimulation model based on 5-year follow-up of the 
Rotterdam Study showed that the gain in total CVD-free life expectancy increased as risk factor levels 
increased. The gain in total CVD-free expectancy decreased with advancing age, whereas 10-year risk for 
CVD mortality, and therefore 10-year risk reduction, increased with age.50 In other primary prevention 
settings, the gains from preventive therapy for CVD have been largest in younger people with high 
lifetime risk for CVD due to high risk factor levels.23 24 51 For example, smoking cessation at age 60, 50, 
40, or 30 years resulted in about 3, 6, 9, and 10 years of life years gained respectively. This indicates that 
the highest lifetime benefit can be gained by reducing risk factors early in life, ideally with lifestyle 
interventions but, if necessary, with drug treatment.52 We illustrate this with our model in figure 3. A 
younger patient with high risk factor levels (Patient A) has the potential to benefit more from preventive 
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therapy on the long term compared to an older patient with lower risk factor levels (Patient C), despite the 
fact that 10-year absolute risk reduction is higher for the older patient in this example.  
In clinical practice, prediction of lifetime benefit in CVD-free life years gained would enable patients (as 
well as clinicians) to better understand the potential benefits of treatment. Such information could help 
patients to participate in the decision-making process about treatment and may also motivate them to 
adhere to therapy. Clinicians and patients can balance the benefit and possible disadvantages of treatment, 
to decide whether preventive medication should be started or stopped. Also, the ability to estimate which 
preventive therapy is most effective (e.g. lipid-lowering, blood pressure-lowering or aspirin treatment) 
can help to decide what treatment should be initiated first, and what treatment can be postponed or not 
prescribed to avoid excessive polypharmacy.  
Using the concept of predicting lifetime benefit for making treatment decisions will result in changing 
characteristics of people eligible for treatment, towards higher proportions of younger people with higher 
risk factor levels (figure 4). This group of people need to be treated over a longer period of time resulting 
in higher treatment costs. It is not clear whether stopping treatment in older people would offset these 
costs and health economic analyses are required to investigate and to establish appropriate thresholds of 
minimum gain in life-years free of CVD  
The strengths of this study include the use of a large number of people from diverse cohorts. Since the 
Swedish and SCI –Diabetes database are registries with information for over 90% of people with T2DM 
in both countries, there is limited selection of people with T2DM, in contrast to trial populations.53 
Therefore, these registries are close to true representations of their populations and this increases the 
generalisability of the DIAL-model to clinical practice. Extensive validation of the DIAL model in large 
and diverse populations supports the use of the DIAL-model in people with T2DM without chronic 
kidney disease (eGFR <30) or metastatic cancer in different parts of the world. Also, validation in the 
population based SCI –Diabetes database made it possible to adapt the model for use in populations with 
high and low CVD event rates. 
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Some limitations of the DIAL model should be considered. Although our model can guide the decision to 
start treatment for the prevention of CVD, it must be emphasised that there are other reasons for people 
with T2DM to start preventive therapy (e.g. prevention of neuropathy, retinopathy, diabetic nephropathy, 
or foot ulcers). The DIAL-model predictions do not incorporate these effects and may, therefore, 
underestimate the total treatment benefits. In addition, some people use preventive medication for other 
indications. For example, lipid lowering drugs are also used for monogenetic dyslipidaemias, 
antihypertensive drugs are used to reduce progression of aneurysms, and diuretics are used for heart 
failure. The DIAL-score may not be applicable to people with such co-morbidities. Additional risk factors 
such as socio-economic status, coronary calcium scores and ethnicity have not been incorporated in the 
model and may have improved performance. However, addition of more risk factors to prediction models 
generally only leads to minor improvements model performance.54 Finally, the initial and most effective 
approaches to primary and secondary prevention of T2DM are lifestyle changes, such as smoking 
cessation or avoidance, sufficient physical activity, healthy diet and, where appropriate, weight loss. 
Clearly prediction of effects of lifestyle interventions would be valuable. However, it is currently not 
feasible to include lifestyle factors in prediction models given the lack of robust estimates of the effect 
size for lifestyle interventions from randomised controlled trials.  
Other limitations of the methods used to develop and validate the DIAL model, and to estimate treatment 
effects should be acknowledged. Baseline predictors such as duration of T2DM, albuminuria, insulin 
treatment, and HbA1c were missing for some people within the validation data. The use of median, 
surrogate, and assumed values for these predictors could lead to the underestimation of the accuracy of 
the model if all data were available.  However such data are often missing in clinical practice and 
prediction tools need to have alternative approaches available for them to be useful in the real world. 
Second, validation could only be performed for 10-year and 5-year predictions due to the limited follow-
up in the included cohorts and trials. Lifetime estimates often go beyond 10-year predictions, and require 
the assumption that rates will be similar for a current 40 year old in 40 years’ time to those of an 80 year 
old today. This is a major assumption but previous studies have shown that lifetime estimates based on 
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the methods we used appear to apply for a survival of up to 17 years.23 Nevertheless, longer-term 
validation would be preferable and will be possible as follow up data accrue in Sweden and Scotland. 
Third, a 5-10% overestimation of predicted risk of CVD and mortality combined was observed in people 
in the highest decile of risk in most external validation datasets. However, in clinical practice, this may 
not be too problematic, since these people are at high risk anyway and the overestimation does not result 
in misclassification or incorrect treatment decisions. Furthermore, possible changes in risk factor levels 
over time were not taken into account. For example, blood pressure and cholesterol were assumed to 
remain stable over time. Also, the lifetime benefits are calculated assuming immediate, lifelong, 
successful (i.e. targets reached) and uninterrupted treatment from their current age onwards. Therefore, 
re-evaluation of CVD-free survival and treatment effects after 5 to 10 years is advised based on our 
validation to ensure valid predictions to guide treatment decisions.   
In conclusion, CVD-free life expectancy as well as the effect of lifelong lipid-lowering, blood pressure-
lowering, and aspirin treatment in terms of CVD-free life years gained can be reliably predicted for 
people with T2DM using readily available characteristics. The DIAL model may facilitate personalised 
treatment and support shared decision-making and patients’ motivation to adhere to prescribed drug-
treatments to reduce CVD risk.  
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Table 1. Baseline characteristics for study populations used in the DIAL model pooled by geographical origin. 
  Derivation   Validation 
  
NDR 
derivation   
NDR 
validation 
Western- 
Europe 
Eastern- 
Europe 
North-
America 
Asia and 
Oceania Scotland 
Group size (n = 292,024)   (n = 97,342) (n = 7,742) (n = 2,142) (n = 14,590) (n = 5,580) (n = 167,731) 
Age (y) 65 (57-74) 65 (57-74) 65 (59-70) 65 (59-71) 63 (58-68) 65 (60-69) 60 (51-68) 
Sex (Male) 164,672 (56%) 54,584 (56%) 5,074 (66%) 949 (44%) 8,488 (58%) 3,196 (57%) 96,989 (58%) 
Current smoking 48,235 (17%) 16,206 (17%) 1,419 (18%) 377 (18%) 1,989 (14%) 741 (13%) 59,434 (35%) 
Duration of diabetes mellitus (y) 2 (0-7) 2 (0-7) 2 (2-5) 7 (3-12) 6 (2-12) 7 (3-12) 0 (0-0) 
Insulin treatment 49,388 (17%) 16,639 (17%) 606 (8%) 43 (2%) 3,587 (25%) 84 (2%) 16,373 (10%) 
Systolic blood pressure (mmHg) 140 (128-150) 140 (128-150) 150 (137-164) 148 (135-163) 139 (127-150) 141 (128-155) 135 (125-145) 
Body mass index (kg/m2)  29 (26-33) 29 (26-33) 29 (26-32) 30 (27-33) 31 (28-35) 26 (24-29) 32 (28-36) 
HbA1c (mmol/mol) 50 (44-59) 50 (44-59) 53 (45-64) 56 (46-69) 63 (55-73) 55 (48-67) 53 (46-65) 
Non-HDL (mmol/L) 3.7 (3.0-4.5) 3.7 (3.0-4.5) 3.8 (3.1-4.6) 4.3 (3.6-5.1) 3.9 (3.1-4.6) 3.8 (3.1-4.6) 3.4 (2.7-4.3) 
eGFR (mL/min/1.73m2; CKD-EPI) 84 (68-96) 84 (68-96) 72 (61-86) 70 (59-83) 81 (67-94) 79 (65-92) 83 (68-96) 
Micro-albuminuria  43,231 (15%) 14,668 (15%) 2,707 (35%) 560 (26%) 2,892 (20%) 1731 (31%) 24,631 (15%) 
Macro-albuminuria 20,526 (7%) 6,832 (7%) 201 (3%) 99 (5%) 761 (5%) 276 (5%) 2,318 (1 %) 
History of CVD 55,896 (19%) 18,674 (19%) 2,618 (34%) 771 (36%) 4,948 (34%) 1784 (32%) 24,853 (15%) 
 
All data are shown as median (inter quartile range) or frequency (%). NDR: Swedisch National Diabetes Registry. Micro-albuminuria was defined 
as an albumin/creatinine ratio 3-30 mg/mmol or urine-albumin 20-300mg/l. Macro-albuminuria was defined as an albumin/creatinine ratio 
>30mg/mmol or urine-albumin >300mg/l. 
 
25 
 
Table 2. Hazard ratios derived from a multi-variable model used in the DIAL model (see footnotes for definitions) 
  
Cox proportional hazard 
function A (vascular 
events) 
  Cox proportional hazard 
function B (non-vascular 
mortality) 
  HR (95% CI)   HR (95% CI) 
Male sex* 0.91 (0.88 - 0.94)*   0.89 (0.87 - 0.91)* 
Current smoking* 1.04 (1.00 - 1.09)*   1.46 (1.43 - 1.50)* 
Duration of T2DM (years) 1.02 (1.01 - 1.02)   1.01 (1.01 - 1.01) 
Insulin therapy* 1.02 (0.98 - 1.06)*   1.04 (1.01 - 1.07)* 
Systolic blood pressure (mmHg) ** 1.06 (0.95 - 1.17)**   1.01 (0.93 - 1.10)** 
Body mass index (kg/m²)** 0.88 (0.81 - 0.97)**   0.89 (0.84 - 0.95)** 
HbA1c (mmol/l) ** 1.15 (1.05 - 1.26)**   1.00 (1.00 - 1.00) 
non-HDL-c (mmol/l) ** 1.16 (1.10 - 1.23)**   0.96 (0.92 - 1.00)** 
eGFR (ml/min/1.73m²)** 0.64 (0.60 - 0.69)**   0.99 (0.99 - 0.99) 
Micro-albuminuria 1.18 (1.14 - 1.22)   1.17 (1.14 - 1.20) 
Macro-albuminuria 1.23 (1.18 - 1.28)   1.24 (1.20 - 1.28) 
History of cardiovascular disease 9.99 (9.63 - 10.36)*   0.25 (0.24 - 0.26)* 
 
 
* Age-dependent variables. Hazard ratios are shown for the median age of 65 years. 
** Transformed variables. Hazard ratios are shown for the 75 percentile versus the 25 percentile (Systolic blood pressure: 150 mmHg vs 128 
mmHg; Body mass index: 33 kg/m² vs 26 kg/m²; HbA1c: 59 mmol/l vs 44 mmol/l; eGFR: 96 ml/min vs 68 ml/min; Non-HDLc: 4.5 mmol/l vs 3.0 
mmol/l). 
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Figure 1. Flowchart describing cohort selection from the Swedish National Diabetes Registry. 
 
 
 
419,533 people with T2DM enrolled 
between 2002-2012 
Excluded:  
- Malignancy (n=25,290) 
- eGFR <30 ml/min (n=4,877) 
389,366 people with T2DM 
Connected with hospital and mortality 
registries (ICD-codes: CVD) 
Model development cohort 
(n=292,024) 
75% 25% 
Internal validation cohort 
(n=97,342) 
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Figure 2: Internal validation (n=97,342) of the predicted 10-year risk. 
 
A) Predicted versus observed 10-year risk of the cause-specific CVD risk (Cox proportional hazard 
function A). B) Predicted versus observed 10-year risk of the non-vascular mortality risk (Cox 
proportional hazard function B; after recalibration). C). Predicted versus observed 10-year risk of CVD 
and all-cause mortality (DIAL-model). 
Dots represent mean risks with 95% confidence intervals of people grouped by deciles of predicted risk.
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Figure 3: Calibration plots in external dataset pooled by geographical region. 
 
Predicted versus observed 5-year risk of CVD and all-cause mortality according to the DIAL-model in 
quintiles of risk in A) Eastern-Europe, B) Western-Europe, C) North-America, and D) Asia and Oceania. 
E) Predicted versus observed 10-year risk of CVD and all-cause mortality according to the DIAL-model 
in deciles of risk in Scotland. 
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Figure 4: Examples of treatment effects of simvastatin 40 mg versus no treatment in people with different 
characteristics. 
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  Patient A Patient B Patient C 
Age (years) 55 65 80 
Sex male female female 
Smoking status no no no 
Duration of T2DM (y) 5 5 10 
Insulin therapy no no no 
Systolic blood pressure (mmHg) 150 145 140 
Body-mass index (kg/m²) 27 27 30 
HbA1c (mmol/mol) 55 55 55 
Non-HDL-c (mmol/l) 5 6 5 
eGFR (ml/min/1.73m²) 70 70 60 
Albuminuria no no micro-albuminuria 
History of CVD yes no yes 
LDL-c (mmol/l) 3.0 4.5 3.0 
10 year-risk (%) 27.1 3.7 46.4 
10-year ARR (%) 5.8 1.2 8.4 
10-year NNT 17 83 12 
CVD-free survival (y) 71.5 85.2 86.6 
Lifetime gain free of CVD (y) 2.9 0.4 1.3 
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Supplemental methods:  
Missing data. 
In the Swedish National Diabetes Registry (NDR) proportions of missing data was 0% for age, sex, and 
outcome status, 15% for systolic blood pressure (SBP), 11% for Hemoglobin A1c (HbA1c), 12% for 
duration of T2DM, 22% for smoking status, 25% for body mass index (BMI), 21% for estimated 
glomerular filtration rate (eGFR), 31% for total cholesterol, 40% for high-density lipoprotein cholesterol 
(HDLc) and 42% for albuminuria. In the SCI –Diabetes database proportions of missing data were 0% for 
age, sex, and outcome status, 9% for SBP, 10% for HbA1c, 12% for eGFR, 22% for smoking status, 32% 
for non-HDLc, 35% for BMI, and 43% for albuminuria. Duration of T2DM was not missing, because the 
population was limited to an incident cohort. In SMART missing data for cholesterol, eGFR, history of 
CVD and albuminuria ranged from 0.05% to 6%. In EPIC-NL missing data was 1% for SBP and history 
of CVD, 3.6% for duration of T2DM, 11.5% for HbA1c, eGFR, cholesterol, HDLc, and 24.8% for type of 
diabetes treatment. In the ACCORD and ADVANCE-trial, missing data ranged from <1% for SBP to 
4.5% for albuminuria. In the ASCOT-trial missing data was 8.3% for plasma glucose and 33.6% for 
eGFR. In the ALLHAT-LLT-trial missing data was <2.0% for BMI, cholesterol, HDLc, and eGFR, and 
20.9% for plasma glucose.  
In EPIC-NL, ASCOT, and ALLHAT-LLT, data was not available for duration of T2DM (ASCOT, 
ALLHAT-LLT), albuminuria (EPIC-NL, ALLHAT-LLT), treatment of T2DM with insulin (ASCOT, 
ALLHAT-LLT) and HbA1c. For validation, duration of T2DM, treatment with insulin, and albuminuria 
were imputed by the median values in Swedish NDR (i.e. 2.0 years duration of T2DM, 17% insulin 
treatment, 15% micro-albuminuria, and 7% macro-albuminuria). 
 
Transformations and non-proportionality of predictors. 
Quadratic transformation of continuous predictors was applied for BMI, SBP, HbA1c, non-HDL-c and 
eGFR for the CVD Cox proportional hazard function and for BMI, SBP, and BMI for the non-vascular 
mortality Cox proportional hazard function. Non-proportionality was observed for sex, smoking, history 
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of CVD and treatment with insulin, in both parts of the Cox proportional hazard functions (i.e. for CVD 
and non-vascular mortality). These predictors are of increasing or decreasing importance with increasing 
age. Therefore, interactions with these predictors and age were included in the model. Supplemental 
figure 1 (CVD) and supplemental figure 2 (non-vascular mortality) visualize the HRs of transformed 
predictors and HRs of predictors depending on age. 
 
Relative treatment effects of meta-analyses and trials translated to lifelong treatment benefit in 
CVD-free life years gained. 
Lipid-lowering treatment: 
The effect of lipid-lowering treatment on CVD depends on estimated reduction in low-density lipoprotein 
cholesterol (LDLc) compared to baseline. A reduction of 1 mmol/l LDLc is related to a hazard ratio of 
0.78.44 45 The percentage decrease of baseline LDLc for different statins and/or ezetimibe for people with 
T2DM are described in meta-analyses.47 48 The individual expected relative risk reduction of CVD is 
calculated by 0.78LDL-reduction in mmol/l, where LDL-reduction in mmol/l is defined as  
Baseline LDL-c multiplied by the expected percentage LDL-c reduction due to intended treatment. 
Blood pressure-lowering treatment: 
The effect of blood pressure-lowering treatment is estimated as a hazard ratio of 0.74 per 10 mmHg for 
people with T2DM with a baseline blood pressure of 140mmHg or higher.46 There is no relative risk 
reduction assumed of lowering blood pressure under 140 mmHg.49  
The individual expected relative risk reduction of CVD is calculated by 0.74(Blood pressure reduction in mmHg/10), 
where blood pressure reduction in mmHg is the blood pressure of the patient minus the target blood 
pressure. This only applies for people with a blood pressure above 140 mmHg. The hazard ratio for blood 
pressure changes under 140mmHg is assumed to be 1. 
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Aspirin treatment: 
The effect of aspirin treatment on CVD differs between people with and without a history of CVD. The 
hazard ratio of aspirin treatment in people without a history of CVD is 0.88 and for patient with a history 
of CVD 0.81.55 56 
Combined individualized treatment effects: 
The hazard ratios of lipid-lowering, blood pressure-lowering, and aspirin treatment are multiplied to 
calculate the relative individualized risk reduction for the combination of treatments. This hazard ratio of 
intended treatment is used in the Cox proportional hazard function for vascular events (A) as shown in 
supplemental table 5 for the estimation of individualized treatment effects.
35 
 
Supplemental table 1. In- and exclusion criteria of the original cohorts and trials and definition of type 2 
diabetes mellitus (T2DM). 
A. In- and exclusion criteria of the study populations 
 Inclusion criteria Exclusion criteria 
Swedish NDR32 People aged 18 years or older with 
T2DM, registered between 2002 and 
2012  
 
Scottish  Care 
Information –
Diabetes database 
People aged 18 years or older with 
T2DM, registered between January 
2004 and June 2016. 
 
SMART36 People aged 18-79 years with T2DM, 
included between 1996 and 2015. 
-Terminal malignancy 
-Not independent in daily activities 
(Rankin scale >3)  
-Not sufficiently fluent in Dutch 
- Estimated glomerular filtration rate 
(eGFR) < 30 ml/min 
EPIC-NL28 People originated from the 
MORGEN and PROSPECT cohort.  
PROSPECT is a prospective cohort 
study among women aged 49–70. 
The MORGEN cohort consists of a 
general population sample of men 
and women aged 20–59 years. People 
with a confirmed diagnosis of T2DM 
were eligible for this study. 
- Estimated glomerular filtration rate 
(eGFR) < 30 ml/min 
ACCORD37 Patient aged 40-79 with T2DM - A medical condition likely to limit 
survival to <3 years or a malignancy other 
than nonmelanoma skin cancer within the 
past 2 years 
- Currently participating in another clinical 
trial 
- Estimated glomerular filtration rate 
(eGFR) < 30 ml/min 
ADVANCE34 People aged 55 years and older with 
a diagnosis of T2DM at the age of 30 
or older.  
A definite indication for long-term insulin 
therapy. 
- Estimated glomerular filtration rate 
(eGFR) < 30 ml/min 
ASCOT30 People aged 40-79 with T2DM and 
two other cardiovascular risk factors 
Previous myocardial infarction, currently 
treated angina, heart failure, or a 
cerebrovascular event within the previous 
3 months. 
- Estimated glomerular filtration rate 
(eGFR) < 30 ml/min 
ALLHAT33 People aged 55 and older with T2DM Symptomatic myocardial infarction or 
stroke within the past 6 months or diseases 
likely to lead to non-cardiovascular death 
over the course of the study 
- Estimated glomerular filtration rate 
(eGFR) < 30 ml/min 
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B. Definition of T2DM 
 
Swedish NDR32 The definition of T2DM was treatment with 1) diet only, 2) oral hypoglycemic 
agents only, or 3) insulin only or combined with oral agents, and onset age of 
diabetes ≥40 years 
Scottish Care 
Information –
Diabetes database 
T2DM was defined using an algorithm which uses information from the clinician 
recorded diabetes type, prescription data (use of and timing of sulphonylureas and 
insulin) and age at diagnosis. 
SMART36 A referral diagnosis of T2DM, self-reported T2DM, a fasting serum glucose ≥7.0 
mmol/L at inclusion with initiation of glucose lowering treatment within one year, 
or the use of oral anti-hyperglycemic agents or insulin at baseline. Participants 
with known type 1 diabetes mellitus were excluded. 
EPIC-NL28 Diagnosis of T2DM was self-reported at baseline. 
ACCORD37 1) Symptoms of diabetes plus casual plasma glucose concentration ≥11.1 mmol/l. 
Casual was defined as any time of day without regard to time since last meal. The 
classic symptoms of T2DM include polyuria, polydipsia, and unexplained weight 
loss for ≥3 months. 2) Fasting plasma glucose ≥7.0 mmol/l. Fasting is defined as 
no caloric intake for at least 8 h for ≥3 months. 3) Stable diabetes therapy for >3 
months. 4) An HbA1c level 7.5%-11% more than 3 months before randomization. 
 
ADVANCE34 People diagnosed with non-insulin-dependent T2DM at age 30 years or older. 
ASCOT30 1) Fasting plasma glucose ≥7 mmol/l and/or random glucose ≥11 mmol/l, 2) Self-
reported T2DM and receiving dietary or drug therapy, or 3) Presence of both 
impaired fasting glucose (≥6 mmol/l) and glucosuria in absence of above two 
criteria. 
ALLHAT33 History of treatment with insulin or oral hypoglycemic agents during the 2 years 
preceding randomization, a fasting baseline glucose level >7.8 mmol/l, or a non-
fasting baseline glucose level >11.1 mmol/l. 
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C. Definition of endpoints. 
Swedish NDR32 Outcome evaluation: All CVD and non-cardiovascular causes of death endpoints were 
retrieved by data linkage with the Swedish Cause of Death Register and the Hospital 
Discharge Register (National Board of Health and Welfare, Sweden). CVD was 
defined as a myocardial infarction, stroke or vascular mortality (ICD-10 codes I20-
I25, I46.0, I46.1, I46.9, I61, I63, and I64). 
Myocardial infarction: Hospitalization due to non-fatal myocardial infarction or 
cardiac arrest. ICD-10 codes: I21, I46.0, I46.1, I46.9. 
Stroke: Hospitalization due to non-fatal stroke. ICD-10 codes: I61,I63, I64 
Cardiovascular mortality: ICD-10 codes I20-I25, I46.0, I46.1, I46.9, I61, I63, and 
I64. 
Scottish  Care 
Information –
Diabetes 
database 
Outcome evaluation: All CVD and non-cardiovascular causes of death endpoints were 
retrieved by data linkage with the National Records of Scotland death registrations 
and the national hospitalization register (Scottish Morbidity Record, SMR01). CVD 
was defined as a myocardial infarction, stroke or vascular mortality (ICD-10 codes 
I20-I25, I46.0, I46.1, I46.9, I61, I63, and I64). 
Myocardial infarction: Hospitalization due to non-fatal myocardial infarction or 
cardiac arrest. ICD-10 codes: I21, I46.0, I46.1, I46.9. 
Stroke: Hospitalization due to non-fatal stroke. ICD-10 codes: I61,I63, I64 
Cardiovascular mortality: ICD-10 codes I20-I25, I46.0, I46.1, I46.9, I61, I63, and 
I64. 
SMART36 Outcome evaluation: During follow-up, people were asked biannually to complete a 
standardized questionnaire on hospital admissions and outpatient clinic visits. If a 
vascular event was reported, hospital discharge letters and results of laboratory and 
radiology examinations were collected. Death was reported by relatives of the 
participant, the general practitioner or the treating specialist. All possible events were 
independently evaluated by three members of the endpoint committee, comprising 
physicians from different clinical departments. 
Myocardial infarction: Fatal and non-fatal myocardial infarction, characterized by at 
least two of the following criteria: 
1. Chest pain for at least 20 minutes not disappearing after administration of nitrates 
2. ST-elevation >1 mm in two following leads or a left bundle branch block on the 
ECG * 
3. CK elevation of at least two times the normal value of CK and an MB-fraction >5% 
of the total CK 
Stroke: Relevant clinical features which have caused an increase in handicap of at 
least one grade on the modified Rankin scale, accompanied by a fresh infarct on a 
repeat CT scan. 
Cardiovascular mortality: -Sudden death: unexpected cardiac death occurring within 
1 hour after onset of symptoms or within 24 hours given convincing circumstantial 
evidence  
-Death from ischemic stroke   
-Death from congestive heart failure  
-Death from myocardial infarction  
-Death from rupture of abdominal aortic aneurysm  
-Vascular death from other cause, i.e. sepsis following stent placement 
EPIC-NL28 Outcome evaluation: Vital status was identified using the municipal population 
register with a loss-to-follow-up of 2.6%. For participants who died, information on 
38 
 
the cause of death was obtained from Statistics Netherlands. Morbidity data were 
provided by the national hospital discharge register (HDR).  Causes of death and 
morbidity have been coded according to the Ninth Revision of the International 
Classification of Diseases (ICD-9) until 1996, and after that according to the Tenth 
Revision of the International Statistical Classification of Diseases (ICD-10). 
Myocardial infarction: Hospitalization due to non-fatal myocardial infarction or 
cardiac arrest. ICD-10 codes I20-I25, I46  or ICD-9 code 410 
Stroke: Hospitalization due to stroke.  ICD-10 codes I60-I63, I65, G45 or ICD-9 
codes 430, 431, 432, 433, 434, 435 
Cardiovascular mortality: ICD-10 codes I20-I25, I46, I60-I63, I65, R96, G45 and 
ICD-9 codes 410, 430, 431, 432, 433, 434, 435 
ACCORD37 Outcome evaluation: Outcomes were adjudicated by a central committee whose 
members were unaware of study-group assignments on the basis of predefined 
criteria. 
Myocardial infarction: The diagnosis of MI is based on the occurrence of a 
compatible clinical syndrome associated with diagnostic elevation of cardiac enzymes 
(ie, an increase in troponin T or troponin I to a level indicating myonecrosis and/or an 
increase in creatine kinase–myocardial band to a level more than twice the upper limit 
of normal). Q-wave MI is defined as the development of new significant Q waves. 
Silent MI is diagnosed when new (compared with the previous 12-lead 
electrocardiogram) significant Q waves are detected by surveillance 
electrocardiography performed every 2 years and at study end in all participants. 
Stroke: Stroke is diagnosed by a focal neurologic deficit that lasts >24 hours, 
associated with evidence of brain infarction or hemorrhage by computed tomography, 
MRI, or autopsy. 
Cardiovascular mortality: Cardiovascular causes of death include fatal MI, 
congestive heart failure, documented arrhythmia, death after invasive cardiovascular 
interventions, death after noncardiovascular surgery, fatal stroke, unexpected death 
presumed to be due to ischemic CVD occurring <24 hours after the onset of 
symptoms, and death due to other vascular diseases (eg, pulmonary emboli, 
abdominal aortic aneurysm rupture). 
ADVANCE34 Outcome evaluation:  An Endpoint Adjudication Committee, masked to treatment 
allocation, reviewed source documentation for all individuals who had a suspected 
primary endpoint or who died during follow-up. Outcomes were coded according to 
the 10th revision of the International Classification of Diseases. 
Myocardial infarction: ICD-10 codes I20-I25, I46 
Stroke: ICD-10 codes I60-I63, I65, G45 
Cardiovascular mortality: ICD-10 codes I20-I25, I46, I60-I63, I65, R96, G45 
ASCOT30 Outcome evaluation:  Each possible study endpoint was reviewed by at least two 
members of an independent Endpoint Committee blinded tot the study treatments 
following standardized study criteria, definitions and algorithms. 
Myocardial infarction: Non-fatal (including silent) myocardial infarction 
Stroke: Any stroke 
Cardiovascular mortality: Death due to any cardiovascular disease (not further 
specified) 
ALLHAT33 Outcome evaluation: The diagnosis of an endpoint was classified by the physician-
investigator at the clinical site based on death certificates or hospital discharge 
summaries. For a random 10% subset of hospitalized (fatal and nonfatal) myocardial 
infarctions and strokes, the Clinical Trials Center will request more detailed 
information. For this subset, in hospital ECGs and enzyme levels (for myocardial 
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infarctions), and neurologists' reports and computed tomography (CT) or magnetic 
resonance imaging (MRI) reports (for strokes) will be evaluated by the study 
Endpoints Committee and the accuracy of the discharge diagnoses assessed. 
Myocardial infarction: Non-fatal myocardial infarction based on hospital discharge 
summaries classified by the physician investigator.  
Stroke: Non-fatal stroke based on hospital discharge summaries classified by the 
physician investigator. 
Cardiovascular mortality: Any death classified by the physician-investigator as 
caused due to cardiovascular disease. 
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Supplemental table 2. Example of a life-table. 
Life 
years 
Cumulative 
survival 
% CVD 
risk 
% non-CVD 
mortality 
55 1.00 2.48% 0.11% 
56 0.97 2.50% 0.13% 
57 0.95 2.28% 0.13% 
58 0.93 2.82% 0.15% 
59 0.90 2.99% 0.18% 
60 0.87 3.38% 0.20% 
61 0.84 3.55% 0.23% 
62 0.81 3.65% 0.27% 
63 0.78 4.02% 0.26% 
64 0.74 3.67% 0.32% 
65 0.71 4.26% 0.37% 
66 0.68 4.42% 0.42% 
67 0.65 4.36% 0.45% 
68 0.62 5.05% 0.51% 
69 0.58 5.31% 0.60% 
70 0.55 5.42% 0.62% 
71 0.51 4.80% 0.72% 
72 0.49 5.36% 0.79% 
73 0.46 6.03% 0.92% 
74 0.42 6.18% 0.99% 
75 0.39 6.43% 1.22% 
76 0.36 6.79% 1.32% 
77 0.33 7.18% 1.54% 
78 0.30 7.86% 1.79% 
79 0.28 7.92% 1.92% 
80 0.25 7.80% 2.33% 
81 0.22 8.70% 2.51% 
82 0.20 8.79% 2.87% 
83 0.18 9.57% 3.29% 
84 0.15 9.54% 3.91% 
85 0.13 9.83% 4.28% 
86 0.11 9.84% 4.83% 
87 0.10 9.73% 5.42% 
88 0.08 10.64% 6.01% 
89 0.07 9.67% 6.46% 
90 0.06 9.51% 6.89% 
91 0.05 9.31% 7.47% 
92 0.04 8.94% 7.83% 
93 0.03 7.24% 7.58% 
94 0.03 6.14% 7.94% 
 
Life-table is of patient example A (figure 3), a 55-year old male, who does not smoke, T2DM since 5 
years, a systolic blood pressure of 150 mmHg, BMI of 27 kg/m2, HbA1c of 55 mmol/mol, Non-HDL-c of 
5 mmol/l, eGFR of 70 ml/min/1.73m2, no albuminuria, and a history of CVD. This patient has a median 
survival free of CVD of 71.5 years and a 10-year CVD-risk of 27.1%. 
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Supplemental table 3. Number of people, recruitment period, follow-up, and number of events. 
Study characteristics Development Geographical validation   
Cohort Recruitment 
period 
Follow-up (years) People after 
exclusion 
Derivation Internal 
validation 
Western-
Europe 
Eastern-
Europe 
North-
America 
Asia & 
Oceania 
Scotland 
Swedish NDR 
(n=419,533) 2002-2012 6.1 (4.1 to 8.5) 389,366 292,024 97,342           
SMART 
(n=1,910) 1996-2014 6.8 (3.5 to 10.5) 1,876     1,876         
EPIC  
(n=524) 1993-1997 14.5 (12.1 to 15.9) 522     522         
ACCORD 
(n=10,251) 2001-2003 4.8 (4.0 to 5.7) 10,242         10,242     
ADVANCE 
(n=11,139) 2001-2002 5.0 (4.5 to 5.7) 11,062     2,921 2,126 433 5,580   
ASCOT 
(n=4,646) 1998-2000 5.5 (5.0 to 6.0) 4,629     2,354         
ALLHAT 
(n=3,903) 1994-1998 4.6 (3.8 to 5.7) 3,865         3,865     
SCI –Diabetes 
database 
(n=167,731) 
2004-2016 5.3 (2.0 to 8.0) 167,731             167,731 
                      
    CVD events 21,910 (8%) 7,352 (8%) 935 (12%) 243 (11%) 1,540 (11%) 575 (10%) 15,288 (9%) 
    Non-vascular deaths 45,579 (16%) 15,093 (16%) 562 (7%) 92 (4%) 285 (5%) 183 (3%) 11,576 (7%) 
NDR: National Diabetes Registry; SMART: Secondary Manifestation of ARTerial disease study; EPIC-NL: European Prospective Investigation 
into Cancer-Netherlands; ACCORD: Action to Control Cardiovascular Risk in Diabetes; ADVANCE: Action in Diabetes and vascular disease: 
preterAx and diamicroN-MR Controlled Evaluation; ASCOT: Anglo-Scandinavian Cardiac Outcomes Trial; ALLHAT-LLT: Lipid Lowering Trial 
component of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. SCI: Scottish Care Information. 
Follow-up years are shown as median (inter quartile range). 
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Supplemental table 4. Baseline characteristics of original cohort and trial data. 
 
  Swedish NDR SMART EPIC-NL ACCORD ADVANCE ASCOT 
ALLHAT-
LLT 
SCI –Diabetes 
database 
Group size (n = 394,152) (n = 1,910) (n = 524) (n = 10,251) (n = 11,139) (n = 4,646) (n = 3,903) (n = 167,731) 
Age (y) 65 (57-74) 61 (54-68) 59 (53-64) 62 (58-67) 66 (61-70) 64 (58-70) 65 (60-71) 60 (51-68) 
Sex (Male) 221,372 (56%) 1,329 (70%) 95 (18%) 6,299 (61%) 6,406 (58%) 3,306 (71%) 1,869 (48%) 96,989 (58%) 
Current smoking 65,135 (17%) 466 (24%) 129 (25%) 1,429 (14%) 1,682 (15%) 887 (19%) 500 (13%) 59,434 (35%) 
Duration of diabetes mellitus (y) 2 (0-7) 2 (2-2) 5 (2-11) 10 (5-15) 7 (3-11) 2 (2-2) 2 (2-2) 0 (0-0) 
Insulin treatment 67,872 (17%) 455 (24%) 125 (24%) 3,582 (35%) 159 (1%) 0 (0%) 0 (0%) 16,373 (10%) 
Systolic blood pressure (mmHg) 140 (128-150) 143 (130-157) 140 (127-156) 135 (125-147) 144 (130-158) 163 (152-176) 146 (137-158) 135 (125-145) 
Body mass index (kg/m2)  29 (26-33) 28 (25-32) 29 (26-32) 32 (28-36) 28 (25-31) 30 (27-33) 30 (27-34) 32 (28-36) 
HbA1c (mmol/mol) 50 (44-59) 51 (44-61) 62 (50-77) 65 (60-74) 55 (48-66) 49 (41-63) 52 (41-70) 53 (46-65) 
Non-HDL (mmol/L) 3.7 (3.0-4.5) 3.5 (2.8-4.4) 3.5 (3.0-4.2) 3.5 (2.9-4.2) 3.8 (3.2-4.6) 4.4 (3.7-5.1) 4.6 (4.1-5.1) 3.4 (2.7-4.3) 
eGFR (CKD-EPI) 84 (67-96) 79 (64-92) 100 (92-108) 83 (69-95) 75 (62-88) 67 (59-77) 74 (62-87) 83 (68-96) 
Micro-albuminuria 59,301 (15%) 452 (24%) 0 (0%) 2,766 (27%) 3,181 (29%) 2,848 (61%) 0 (0%) 24,631 (15%) 
Macro-albuminuria 29,462 (7%) 83 (4%) 0 (0%) 752 (7%) 513 (5%) 0 (0%) 0 (0%) 2,318 (1 %) 
History of CVD 50,615 (13%) 1,317 (69%) 63 (12%) 3,609 (35%) 3,589 (32%) 642 (14%) 1,168 (30%) 24,853 (15%) 
 
All data are shown as median (inter quartile range) or frequency (%). NDR: National Diabetes Registry. SCI: Scottish Care Information. Micro-
albuminuria was defined as an albumin/creatinine ratio 3-30 mg/mmol or urine-albumin 20-300mg/l. Macro-albuminuria was defined as an 
albumin/creatinine ratio >30mg/mmol or urine-albumin >300mg/l. 
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Supplemental table 5. Calculation formulas of cause-specific 1-year survivals. 
                    
  Vascular Cox proportional hazard function (A)         
                    
  1-year survival = (age-specific 1-yr baseline survival¥)^exp(A)   
                    
  A = -2.432709 (if male) + 0.035983*age (if male) - 0.08603257*(BMI - 30) + 0.001155281*(squared BMI - 
30²) - 0.6910912 (if smoking) + 0.01127745*age (if smoking) - 0.02365684*(SBP-140) + 
0.00009386*(squared SBP - 140²)  + 0.2632915*(nonHDL-3.8) - 0.02153226*(squared nonHDL - 3.8²) + 
0.02274024*(HbA1c-50) - 0.0001292752*(squared HbA1c - 50²) - 0.01172895*(eGFR-80) - 
0.00002497421*(squared eGFR - 80²) + 0.1654953 (if micro-albuminuria) + 0.2061535 (if macro-
albuminuria) + 0.01650379*(diabetes duration) - 0.4734714 (if history of CVD) + 0.04268836*age (if history 
of CVD) - 0.8525590 (if insulin treatment) + 0.01344922*age (if insulin treatment) + LN(Hazard Ratio of 
intended treatment)§ + 1.763233 (if high risk county) 
  
    
    
    
    
    
    
                    
  Non-vascular mortality Cox proportional hazard function (B)       
                    
  1-year survival = (age-specific 1-yr baseline survival¥)^exp(B)   
                    
  B = -1.933780 (if male) + 0.02801824*age (if male) - 0.1325985*(BMI - 30) + 0.001977846*(squared BMI - 
30²) - 0.08033368 (if smoking) + 0.004628002*age (if smoking) - 0.02241861*(SBP-140) + 
0.00008235097*(squared SBP - 140²)  + 0.1612940*(nonHDL-3.8) - 0.01791413*(squared nonHDL - 3.8²) + 
0.002996913*(HbA1c-50) - 0.008377349*(eGFR-80) + 0.1574689 (if micro-albuminuria) + 0.2131683 (if 
macro-albuminuria) + 0.007551427*(diabetes duration) - 3.783736 (if history of CVD) + 0.03680227*age (if 
history of CVD) - 0.3656307 (if insulin treatment) + 0.006264885*age (if insulin treatment) + 0.2164599 (if 
low risk country) - 0.07736502 (if high risk county) 
  
    
    
    
    
    
                    
 
¥ Age-specific baseline survivals are shown in Supplemental Table 6 for both Cox proportional hazard 
functions. 
§ LN(Hazard ratio of intended treatment) is 0 if there is no estimation of treatment effects. The 
calculation of the hazard ratio of intended treatment is explained in the methods and supplemental 
methods 
BMI: Body mass index in kg/m2; SBP: Systolic blood pressure in mmHg; non-HDLc: non-high-density 
cholesterol in mmol/l; HbA1c: Hemoglobin A1c in mmol/l; eGFR: estimated glomerular filtration rate in 
ml/min. 
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Supplemental table 6. Age-specific baseline survivals. 
 
             
Age 
1-year survival 
free of stroke or 
MI* 
1-year survival for 
non-cardiovascular 
mortality** 
 
Age 
1-year survival 
free of stroke 
or MI* 
1-year survival for 
non-cardiovascular 
mortality** 
             
30 0.99828 0.99567  63 0.99670 0.99118 
31 1.00000 1.00000  64 0.99722 0.99009 
32 1.00000 0.99662  65 0.99700 0.98919 
33 0.99883 0.99860  66 0.99712 0.98854 
34 1.00000 0.99685  67 0.99738 0.98835 
35 0.99910 0.99835  68 0.99718 0.98756 
36 0.99857 0.99906  69 0.99726 0.98650 
37 0.99825 0.99843  70 0.99741 0.98692 
38 1.00000 0.99766  71 0.99789 0.98557 
39 1.00000 0.99591  72 0.99782 0.98523 
40 0.99929 0.99778  73 0.99772 0.98390 
41 0.99815 0.99707  74 0.99784 0.98374 
42 0.99922 0.99625  75 0.99792 0.98132 
43 0.99824 0.99535  76 0.99796 0.98098 
44 0.99781 0.99678  77 0.99800 0.97924 
45 0.99770 0.99579  78 0.99797 0.97734 
46 0.99857 0.99615  79 0.99811 0.97722 
47 0.99807 0.99548  80 0.99828 0.97400 
48 0.99757 0.99531  81 0.99822 0.97375 
49 0.99696 0.99481  82 0.99834 0.97187 
50 0.99793 0.99433  83 0.99832 0.96976 
51 0.99722 0.99507  84 0.99845 0.96625 
52 0.99692 0.99452  85 0.99852 0.96537 
53 0.99684 0.99457  86 0.99863 0.96327 
54 0.99626 0.99429  87 0.99875 0.96126 
55 0.99621 0.99389  88 0.99873 0.95968 
56 0.99647 0.99322  89 0.99894 0.95926 
57 0.99702 0.99382  90 0.99907 0.95922 
58 0.99659 0.99312  91 0.99913 0.95844 
59 0.99665 0.99210  92 0.99923 0.95911 
60 0.99649 0.99200  93 0.99943 0.96285 
61 0.99659 0.99134  94 0.99955 0.96348 
62 0.99676 0.99049        
 
Age-specific baseline survivals for centered continues variables with a systolic blood pressure of 140 
mmHg, BMI of 30 kg/m², HbA1c of 50 mmol/l, non-HDL-c of 3.8 mmol/l, and eGFR of 80 ml/min. 
*Based on Cox proportional hazard function A for cardiovascular disease. **Based on Cox proportional 
hazard function B for non- cardiovascular mortality 
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Supplemental table 7. Discrimination of the DIAL model and Cox proportional hazard functions A and 
B for internal (10-year risks) and external validation (5-year risks, except Scotland: 10-year risks). 
 
  Discrimination of estimated vs observerd risk  
A. Cardiovascular 
disease 
B. Non-vascular 
mortality 
C. Combined model 
(DIAL model) 
Validation cohort       
Swedish NDR (n=97,324) 0.83 (0.83-0.84) 0.72 (0.72-0.73) 0.77 (0.76-0.77) 
Western-Europe (n=7,742) 0.65 (0.63-0.67) 0.62 (0.60-0.65) 0.66 (0.64-0.67) 
Eastern-Europe (n=2,142) 0.64 (0.60-0.67) 0.59 (0.52-0.66) 0.68 (0.65-0.71) 
North-America (n=14,590) 0.64 (0.62-0.65) 0.61 (0.58-0.63) 0.64 (0.63-0.66) 
Asia and Oceania (n=5,580) 0.64 (0.62-0.66) 0.61 (0.57-0.66) 0.65 (0.63-0.67) 
SCI –Diabetes database 
(n=167,731) 0.64 (0.64-0.65) 0.67 (0.67-0.68) 0.69 (0.69-0.70) 
 
 
NDR: National Diabetes Registry. SCI: Scottish Care Information.
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Supplemental figure 1. Hazard ratios and 95% CI for transformed and age-dependent variables of the 
cause-specific cumulative incidence model for cardiovascular disease.  
 
 
 
 
 
A-E. Quadratic relation between cardiovascular disease (CVD) and A) systolic blood pressure; B) Body-
mass index; C) Non-HDL-c; D) HbA1c; E) eGFR. 
F-I: Relation between age and the effect of F) sex; G) smoking; H) insulin therapy; I) history of CVD on 
the risk of CVD.  
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Supplemental figure 2. Hazard ratios and 95% CI for transformed and age-dependent variables of the 
cause-specific cumulative incidence model for non-cardiovascular mortality.  
 
 
 
A-C. Quadratic relation between non-cardiovascular mortality and A) systolic blood pressure; B) Body-
mass index; C) Non-HDL-c. 
D-G: Relation between age and the effect of D) sex; E) smoking; F) insulin therapy; G) history of CVD 
on the risk of non-cardiovascular mortality. 
